Healthcare shares are flat to higher in pre-market trade.
Navidea Biopharmaceuticals ( NAVB ) is up 19% in pre-market trade, easing off even steeper gains after saying that the U.S. Food and Drug Administration has granted Fast Track designation to its head and neck cancer Lymphoseek diagnostic tool.
Lymposeek is an injection that detects lymph nodes in patients with head and neck cancer. The Fast Track program is designed to facilitate the development and expedite the review of drug candidates intended to treat serious or life-threatening conditions, and that demonstrate the potential to address unmet medical needs. Navidea said it plans to file a supplemental New Drug Application for Lymposeek before year end.
And, Henry Schein ( HSIC ) said its board has approved a $300 million increase to its share buyback program.
The provider of health care products and services to office-based dental, animal and medical practitioners said its $300 million buyback program announced in Nov. 2012 has about $12.3 million remaining authorized for buybacks.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.